e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Lung cancer: treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of radiotherapy (RTH) in long-term survival limited disease (LD) small cell lung cancer (SCLC) patients (pts) treated in the National TB and Lung Diseases Research Institute
P. Remiszewski, K. Roszkowski-Sliz, B. Roszkowska-Sliz, E. Wiatr, J. Zych, E. Rowinska-Zakrzewska (Warsaw, Poland)
Source:
Annual Congress 2002 - Lung cancer: treatment
Session:
Lung cancer: treatment
Session type:
Thematic Poster Session
Number:
2927
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Remiszewski, K. Roszkowski-Sliz, B. Roszkowska-Sliz, E. Wiatr, J. Zych, E. Rowinska-Zakrzewska (Warsaw, Poland). The role of radiotherapy (RTH) in long-term survival limited disease (LD) small cell lung cancer (SCLC) patients (pts) treated in the National TB and Lung Diseases Research Institute. Eur Respir J 2002; 20: Suppl. 38, 2927
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Imaging of complicated pneumonia: what is new?
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Related content which might interest you:
Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT)
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Muldisciplinary conference (MDC), oncological program (OP) and practice guidelines (GL): The experience of the lung cancer (LC) clinic of a cancer hospital
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
Biological dosimetry in lung cancer (LC) patients treated with fractionated radiotherapy (RT)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Lung cancer in Berlin – NET of the lung; analysis of subgroups and impact on survival (2000 – 2008)
Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer
Year: 2013
Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)?
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts
Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer
Year: 2013
Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Comorbitities, responses and survival in pts with NSCLC
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Treatment and survival in patients with pulmonary carcinoid tumours; an updated analysis from the UK national lung cancer audit
Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features
Year: 2015
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut)
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
European treatment guidelines: small cell lung cancer (SCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Cancer recurrence in surgically treated non small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 755s
Year: 2006
Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care.
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
Prognostic systems in advanced non small cell lung cancer (NSCLC): A validation study by the European Lung Cancer Working Party (ELCWP)
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept